C Caux’s team – S Depil group - Development of immunotherapies targeting non-conventional tumor antigens- at the Cancer Research Center of Lyon, France.

Description

Human Endogenous Retroviruses (HERVs) represent 8% of the human genome. Most HERV genes are non- functional due to DNA recombination, mutations, and deletions, but some conserve open reading frames. HERVs expression is low or null in normal cells. However, they are over expressed in some tumors due to epigenetic dysregulation. HERV retroviral gene products may act as tumor antigens activating both T-cell and B-cell responses in cancer patients. Our group has developed new bioinformatics-based methods to analyze the retrotranscriptome and identify HERV-derived shared epitopes associated to tumors.

As a bioinformatician, you will contribute to the in silico identification of original therapeutic targets in cancer that will be further validated in vitro. You will contribute to the development of existing pipelines and will reproduce the analysis on different data sets. A strong implication in the overall project will be asked.

Requirements

• PhD in bio-informatics, informatics, mathematics or related field

• Knowledge in mathematical modeling, statistics/biostatistics

• Knowledge in new generation sequencing data analysis (RNA-seq and single cell RNA-seq), from quality

  control to data analysis

• Proficiency in at least one common programming tool (R, Python)

• Familiarity with high-performance computing resources and linux environment

• Background in biology mainly in immunology is a plus